Trustmark Bank Trust Department Grows Stake in Eli Lilly and Company $LLY

Trustmark Bank Trust Department raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.8% during the second quarter, HoldingsChannel.com reports. The firm owned 3,853 shares of the company’s stock after buying an additional 176 shares during the period. Trustmark Bank Trust Department’s holdings in Eli Lilly and Company were worth $3,004,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Lazard Freres Gestion S.A.S. raised its position in shares of Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC increased its stake in Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares in the last quarter. Capital Advisors Inc. OK raised its holdings in shares of Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after buying an additional 429 shares during the last quarter. Family CFO Inc acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $54,000. Finally, Duquesne Family Office LLC grew its holdings in shares of Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.7%

Shares of LLY stock opened at $1,074.94 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The stock has a market cap of $1.02 trillion, a P/E ratio of 70.26, a P/E/G ratio of 1.21 and a beta of 0.43. The stock has a 50 day moving average of $889.37 and a 200 day moving average of $799.60. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LLY. HSBC raised their target price on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Truist Financial lifted their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a research report on Monday, November 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,047.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.